Di Bisceglie et al., 1990 - Google Patents
Antiviral Therapy of Chronic Viral Hepatitis.Di Bisceglie et al., 1990
- Document ID
- 3706609137371236857
- Author
- Di Bisceglie A
- Hoofnagle J
- Publication year
- Publication venue
- American Journal of Gastroenterology (Springer Nature)
External Links
Snippet
GI drug column Antiviral Therapy of Chronic Viral Hepatitis Page 1 0002-9270/90/8506-0650
THE AMERICAN JOURNAL OF GASTROENTEROLOGY Copyright© 1990 by Am. Coll. of
Gastroenterology VoL85, No. 6, 1990 Printed in USA GI drug column The ACG Committee on …
- 238000002560 therapeutic procedure 0 title abstract description 42
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S514/00—Drug, bio-affecting and body treating compositions
- Y10S514/893—Liver disorder
- Y10S514/894—Hepatitis
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Niro et al. | Treatment of hepatitis D | |
| Chien et al. | Efficacy of thymosin α1 in patients with chronic hepatitis B: a randomized, controlled trial | |
| Liaw et al. | Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: a randomized controlled trial | |
| Dienstag et al. | Hepatitis B vaccine administered to chronic carriers of hepatitis B surface antigen | |
| Diodati et al. | Treatment of chronic hepatitis C with recombinant human interferon-α2a: results of a randomized controlled clinical trial | |
| Gaudin et al. | The French experience of treatment of chronic type D hepatitis with a 12‐month course of interferon alpha‐2B. Results of a randomized controlled trial | |
| Omata et al. | Histological changes of the liver by treatment of chronic non-A, non-B hepatitis with recombinant leukocyte interferon alpha: comparison with histological changes in chronic hepatitis B | |
| Menne et al. | Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-β-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection | |
| Fattovich et al. | Levamisole therapy in chronic type B hepatitis: results of a double-blind randomized trial | |
| Di Bisceglie et al. | Antiviral Therapy of Chronic Viral Hepatitis. | |
| Liaw et al. | Effects of prednisolone pretreatment in interferon alfa therapy for patients with chronic non‐A, non‐B (C) hepatitis | |
| Marcellin et al. | Prolonged interferon‐alpha therapy of hepatitis B virus‐related decompensated cirrhosis | |
| SHEEN et al. | Severe clinical rebound upon withdrawal of corticosteroid before interferon therapy: incidence and risk factors | |
| Farhat et al. | Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B | |
| Anderson et al. | Randomised controlled trial of lymphoblastoid interferon for chronic active hepatitis B. | |
| Alexander et al. | Chronic viral hepatitis | |
| Thomas et al. | Viruses and immune reactions in the liver | |
| Lok | Antiviral therapy of the Asian patient with chronic hepatitis B | |
| Örmeci | Short‐and long‐term effects of treatment of chronic hepatitis B and delta virus by IFN | |
| Perez et al. | A controlled trial of high dose interferon, alone and after prednisone withdrawal, in the treatment of chronic hepatitis B: long term follow up. | |
| Laskus et al. | Exacerbation of chronic active hepatitis type B after short-term corticosteroid therapy resulting in fatal liver failure. | |
| Tassopoulos et al. | Lamivudine therapy in patients with anti HBe positive chronic hepatitis B; end of treatment analysis | |
| Müller et al. | Low dose alpha interferon treatment in chronic hepatitis B virus infection. | |
| Ersöz et al. | Interferon re-treatment for resistance to lamivudine plus interferon treatment | |
| Terranova et al. | Treatment of chronic hepatitis C with recombinant interferon alpha 2b |